​Effective June 28, 2024, JYNNEOS vaccine has been added to the PrEP-AP formulary.

JYNNEOS is a United States Food and Drug Administration approved vaccine indicated for the prevention of mpox and smallpox infection in adults who are at high risk for either of these infections. In 2022, a global outbreak of mpox occurred that disproportionately impacted gay, bisexual, and other men who have sex with men. Although the number of mpox infections has declined substantially since 2022, mpox transmission has persisted in California in 2023 and 2024. Fortunately, JYNNEOS effectively prevents most mpox infections and among vaccinated individuals who still acquire mpox infection, symptoms are typically mild. JYNNEOS is a two-dose vaccine and most people with an indication for PrEP will also have an indication for mpox vaccination. CDPH recommends offering the mpox vaccine to all patients enrolled in PrEP-AP if they have not completed the 2-dose vaccination series (unless previously diagnosed with mpox). In addition, patients who have only received one dose of JYNNEOS should still receive their second dose as soon as possible even if the first dose was provided in 2022. See the Centers for Disease Control and Prevention Clinical Considerations for Use of JYNNEOS Vaccine to learn more about the JYNNEOS vaccine and see CDPH Immunization Recommendations for Gay, Bisexual, and Other Men Who Have Sex with Men (PDF) for vaccination schedule information.

In addition to being available in pharmacies, the JYNNEOS vaccine will also be available to PrEP-AP clients for administration in a clinical setting. For a full list of PrEP-related services covered by PrEP-AP, along with instruction for providers to bill PrEP-AP for administration, please see the PrEP-AP Resources webpage here: PrEP-AP Clinically Administered Medications. Uninsured, confidential, immediate access, and minor clients must receive physician-administered medications from our contracted clinical providers who may be located here: PrEP-AP Clinical Providers and Enrollment Sites. PrEP-AP requests that you share this information with your clinical leadership team and local prescribers. The PrEP-AP formulary (PDF) has been updated to reflect the addition of the JYNNEOS vaccine.​

If you have any questions regarding this new PrEP-AP benefit, please email PrEP-AP at PrEP.Support@cdph.ca​​.gov .

Thank you,

​​​

Joseph Lagrama,

ADAP Branch Chief      

California Department of Public Health​